- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 -
BEDFORD, Mass., August 5, 2021 – Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company’s Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children’s Hospital of Philadelphia. She was also recently named President of the American Society of Gene & Cell Therapy (ASGCT). Dr. Davidson has founded several successful biotechnology companies, including Spark Therapeutics, now a member of the Roche Group, which developed and commercialized the first adeno-associated virus (AAV) vector gene therapy for a genetic disease in the U.S.
“We have valued Dr. Davidson’s input and guidance on our SAB as we have progressed our gene therapy and gene editing platform and clinical programs, including plans to have two PKU trials, a Hunter syndrome trial and expand our pipeline with a named development candidate for PNH from our GTx-mAb platform this year,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Since joining our SAB, Dr. Davidson’s passion for and dedication to scientific innovation and developing new approaches to targeting devastating diseases, including those with CNS manifestations, has added to our collective expertise. We look forward to her continued leadership as Chair as we advance our AAVHSC platform.”
Prior to her current role, Dr. Davidson held the Roy J. Carver Biomedical Research Chair and was the Vice Chair for Research in the Department of Internal Medicine at the University of Iowa. In addition to co-founding Spark, Dr. Davidson’s important contributions to the biotechnology industry include co-founding Talee Bio (now Spirovant Sciences, Inc.) and serving on multiple scientific advisory boards. Dr. Davidson has received several prestigious honors and recognitions throughout her career, including election to the National Academy of Medicines, the American Academy of Arts and Sciences and the College of Physicians in Philadelphia. She was also awarded the F.E. Bennett Memorial Lectureship Award from the American Neurological Association, the Mathilde Solowey Award from the National Institutes of Health and the S.J. DeArmond Lecturer from the American Association of Neuropathologists. She has editorial responsibilities at peer-reviewed journals, including Molecular Therapy and Human Molecular Genetics, in addition to authoring hundreds of scientific papers. Dr. Davidson received her B.S. in Biology from Nebraska Wesleyan University and her Ph.D. in Biological Chemistry from the University of Michigan.
“It has been a pleasure working with the Homology team as the Company translated an important scientific discovery into a genetic medicines platform to develop potential therapies for patients who have limited or no other treatment options,” said Dr. Davidson. “I look forward to assuming a greater role in directing the Scientific Advisory Board and continuing to collaborate with my colleagues as Homology expands its platform and presence in the clinic this year.”
About Homology Medicines, Inc.
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by targeting the underlying cause of the disease. The Company’s lead clinical program, HMI-102, is a gene therapy for adults with phenylketonuria (PKU) and additional programs focus on gene editing in PKU, lysosomal storage disorders including Hunter syndrome, paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases and believes that its data, internal manufacturing capabilities and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the initiation of clinical trials in PKU and Hunter syndrome and for naming a development candidate for PNH; our beliefs regarding our manufacturing capabilities; our position as a leader in the development of genetic medicines; and our participation in upcoming presentations and conferences. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities of our manufacturing facility; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.